2024
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial
Lassen M, Ostrominski J, Inzucchi S, Claggett B, Kulac I, Jhund P, de Boer R, Hernandez A, Kosiborod M, Lam C, Martinez F, Shah S, Desai A, Petersson M, Langkilde A, Docherty K, McMurray J, Solomon S, Vaduganathan M. Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose‐lowering therapy: A pre‐specified analysis of the DELIVER trial. European Journal Of Heart Failure 2024, 26: 1539-1548. PMID: 38745498, DOI: 10.1002/ejhf.3269.Peer-Reviewed Original ResearchConceptsBackground glucose-lowering therapyLeft ventricular ejection fractionGlucose-lowering therapySodium-glucose cotransporter 2 inhibitorsHeart failureClinical outcomesComposite of worsening HFPrimary outcomeInsulin useBenefits of dapagliflozinVentricular ejection fractionEffects of dapagliflozinType 2 diabetesEjection fractionRandomized patientsMetformin useConcomitant metforminCardiovascular deathFollow-upContemporary guidelinesDapagliflozinTreatment effectsDELIVER trialTreatment benefitT2D
2023
Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease
Tan X, Liang Y, Rajpura J, Yedigarova L, Noone J, Xie L, Inzucchi S, de Havenon A. Once-weekly glucagon-like peptide-1 receptor agonists vs dipeptidyl peptidase-4 inhibitors: cardiovascular effects in people with diabetes and cardiovascular disease. Cardiovascular Diabetology 2023, 22: 319. PMID: 37985992, PMCID: PMC10662529, DOI: 10.1186/s12933-023-02051-8.Peer-Reviewed Original ResearchConceptsHealth care resource utilizationAtherosclerotic cardiovascular diseaseGLP-1 RAsCause health care resource utilizationPeptide-1 receptor agonistsDipeptidyl peptidase-4 inhibitorsDPP-4i usersPeptidase-4 inhibitorsMyocardial infarctionMedical costsDPP-4iIschemic strokeReceptor agonistCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsWeekly glucagon-like peptide-1 receptor agonistWeekly GLP-1 RAsCause ER visitsCause hospitalization costsCause medical costsNew adult usersClinical cardiovascular outcomesObservational cohort studyType 2 diabetesCause outpatient visits
2021
ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL
Sharma A, Inzucchi S, Testani J, Ofstad A, Fitchett D, Mattheus M, Verma S, Zannad F, Wanner C, Kraus B. ASSOCIATION OF KIDNEY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. Canadian Journal Of Cardiology 2021, 37: s62-s63. DOI: 10.1016/j.cjca.2021.07.130.Peer-Reviewed Original ResearchEMPA-REG OUTCOME trialKidney eventsOutcome trialsPlacebo armMyocardial infarctionType 2 diabetes mellitusLower baseline eGFRMI/strokeSubsequent CV eventsRisk of hospitalizationCoronary artery diseaseType 2 diabetesHigh uric acidUse of therapiesAssociation of kidneyBaseline eGFRCV eventsCV outcomesSubsequent HHFCardiovascular outcomesHF outcomesArtery diseaseBaseline factorsDiabetes mellitusHeart failure319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial
KAHL S, OFSTAD A, ZINMAN B, WANNER C, SCHUELER E, INZUCCHI S, RODEN M. 319-OR: Effects of Empagliflozin on Markers of Liver Steatosis and Fibrosis and Their Relation to Cardiorenal Outcomes in the EMPA-REG OUTCOME Trial. Diabetes 2021, 70 DOI: 10.2337/db21-319-or.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseNAFLD fibrosis scoreCardiorenal outcomesFibrosis riskEMPA-REG OUTCOMELiver fat contentRisk of steatosisEffect of empagliflozinFatty liver diseaseType 2 diabetesCause deathDaily empagliflozinSteatosis indexHeart failureFibrosis scoreLiver diseaseCox regressionCardiovascular diseaseHigh riskEmpagliflozinPlaceboSteatosisRisk categoriesBaselineMeasures analysisEmpagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial
Vaduganathan M, Sattar N, Fitchett D, George J, Ofstad A, Verma S, Mattheus M, Wanner C, Inzucchi, Zinman B, Butler J. Empagliflozin facilitates sustained insulin dose reductions in patients with type 2 diabetes and cardiovascular disease: the EMPA-REG OUTCOME trial. Diabetologie Und Stoffwechsel 2021, 16: s18-s19. DOI: 10.1055/s-0041-1727336.Peer-Reviewed Original Research
2020
380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM)
LIPSKA K, DOYLE M, CENGIZ E, DROZDOWICZ B, GILL T, MURPHY T, INZUCCHI S. 380-P: Hypoglycemia among Nursing Home Residents with Diabetes Detected by Continuous Glucose Monitoring (CGM). Diabetes 2020, 69 DOI: 10.2337/db20-380-p.Peer-Reviewed Original ResearchContinuous glucose monitoringNursing home residentsHome residentsNursing homesConsecutive blood glucose levelsFlash continuous glucose monitoringPatients 65 yearsChronic kidney diseaseFrequency of hypoglycemiaLexicon PharmaceuticalsType 2 diabetesBlood glucose levelsWilcoxon rank sum testRank sum testMannKind CorporationAdvisory PanelConnecticut nursing homesADL disabilityMedian ageKidney diseaseNovo Nordisk A/SCGM periodGlucose levelsHypoglycemiaLong-term residents1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial
NEELAND I, ELIASSON B, KASAI T, MARX N, ZINMAN B, INZUCCHI S, WANNER C, ZWIENER I, WOJECK B, YAGGI H, JOHANSEN O. 1128-P: Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial. Diabetes 2020, 69 DOI: 10.2337/db20-1128-p.Peer-Reviewed Original ResearchObstructive sleep apneaNew-onset obstructive sleep apneaCardiovascular diseaseDohme Corp.Novo Nordisk A/SMundipharma InternationalMerck SharpEli LillyEMPA-REG OUTCOMEIncident obstructive sleep apneaFavorable metabolic effectsSanofi-AventisSystolic blood pressureCoronary artery diseaseType 2 diabetesAdvisory PanelEMPA-REGOSA statusPhilips RespironicsSanofi GenzymeSevere obesityArtery diseaseBlood pressureWaist circumferenceSleep apnea131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome
INZUCCHI S, ZINMAN B, WANNER C, FITCHETT D, ANKER S, POCOCK S, KASPERS S, GEORGE J, JOHANSEN O, JAMAL W, HANTEL S, LUND S. 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes 2020, 69 DOI: 10.2337/db20-131-lb.Peer-Reviewed Original ResearchAtherosclerotic cardiovascular diseaseEMPA-REG OUTCOMEEffect of empagliflozinTotal burdenEli LillyHeart failure riskType 2 diabetesNervous system disordersTotal eventsAdvisory PanelSt. Jude MedicalLowest NNTMundipharma InternationalSanofi GenzymeCause hospitalizationCause mortalityCardiovascular mortalityFrequent hospitalizationsDohme Corp.Novo Nordisk A/SCardiovascular diseaseCardiac dimensionsHospitalization categoriesSystem disordersEmpagliflozin927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4
PRATLEY R, BAUER R, INZUCCHI S, KHUNTI K, KREINER E, LAURSEN P, MEIER J. 927-P: Effect of Oral Semaglutide with or without Background SGLT2i in Patients with T2D: Subgroup Analysis of PIONEER 4. Diabetes 2020, 69 DOI: 10.2337/db20-927-p.Peer-Reviewed Original ResearchNovo Nordisk A/SDohme Corp.Oral semaglutideMerck SharpGLP-1RAsSanofi-AventisNovartis AGRoche PharmaSGLT2 inhibitorsSubgroup analysisEli LillyGlucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsDaily oral semaglutideTrial product estimandGastrointestinal adverse eventsLexicon PharmaceuticalsSubgroup of patientsJanssen Scientific AffairsType 2 diabetesBayer AGBoehringer Ingelheim PharmaceuticalsAdvisory PanelSubcutaneous liraglutideT2D duration28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME
VERMA S, LEITER L, SHARMA A, ZINMAN B, MATTHEUS M, FITCHETT D, GEORGE J, OFSTAD A, WANNER C, INZUCCHI S. 28-OR: How Early after Treatment Initiation Are the CV Benefits of Empagliflozin Apparent? A Post Hoc Analysis of EMPA-REG OUTCOME. Diabetes 2020, 69 DOI: 10.2337/db20-28-or.Peer-Reviewed Original ResearchCV deathEMPA-REG OUTCOMEAtherosclerotic cardiovascular diseaseHazard ratioNovo Nordisk A/SJanssen PharmaceuticalsBristol-Myers SquibbTreatment initiationEli LillyEMPA-REG OUTCOME trialCox proportional hazards modelAdvisory PanelBenefits of empagliflozinRisk of HHFRisk of hospitalizationNumber of patientsType 2 diabetesProportional hazards modelCumulative incidence curvesNovartis Pharmaceuticals CorporationPost Hoc AnalysisBayer AGBoehringer Ingelheim PharmaceuticalsEmpagliflozin 10Empagliflozin doses
2019
Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial
Kosiborod M, Nassif M, Windsor S, Tang F, Khariton Y, Austin B, Umpierrez G, Lamba S, Katz S, Fong M, Husain M, Inzucchi S, Mcguire D, Pitt B, Scirica B. Effects of Dapagliflozin on Biomarkers, Symptoms and Functional Status in Patients with Heart Failure with Reduced Ejection Fraction with and without Diabetes - The Define-HF Trial. Journal Of Cardiac Failure 2019, 25: 937-938. DOI: 10.1016/j.cardfail.2019.11.005.Peer-Reviewed Original ResearchPlacebo-controlled trialReduced ejection fractionEffect of dapagliflozinHeart failureFunctional statusSGLT-2iEjection fractionML/min/m2Double-blind placebo-controlled trialCo-primary end pointsDisease-specific health statusHigh-risk patient populationLarge cardiovascular outcome trialsManifest heart failureUrgent HF visitsKey secondary endpointCardiovascular outcome trialsMajority of patientsMin/m2Type 2 diabetesPg/mLExploratory endpointsHF visitsHFrEF patientsSGLT2i dapagliflozinURIC ACID LEVELS PREDICT CARDIORENAL OUTCOMES AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME
Verma S, Qiuhe J, Bhatt D, Mazer C, Al-Omran M, Inzucchi S, Wanner C, Ofstad A, Zwiener I, George J, Zinman B, Fitchett D. URIC ACID LEVELS PREDICT CARDIORENAL OUTCOMES AND CARDIOVASCULAR DEATH IN PATIENTS WITH TYPE 2 DIABETES: A SUB-ANALYSIS OF EMPA-REG OUTCOME. Canadian Journal Of Cardiology 2019, 35: s139. DOI: 10.1016/j.cjca.2019.07.554.Peer-Reviewed Original ResearchP6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease
McGuire D, Zinman B, Inzucchi S, Anker S, Wanner C, Kaspers S, Von Eynatten M, Johansen O, Elsasser U, Pocock S, Fitchett D, Jamal W, Hantel S, Lund S. P6270Empagliflozin reduces the total burden of first and recurrent hospitalisations in patients with type 2 diabetes and established cardiovascular disease. European Heart Journal 2019, 40: ehz746.0869. DOI: 10.1093/eurheartj/ehz746.0869.Peer-Reviewed Original ResearchEMPA-REG OUTCOME trialEffect of empagliflozinCause hospitalisationType 2 diabetesHospitalisation eventsOutcome trialsHeart failureCardiovascular diseaseMajor adverse CV eventsTotal burdenAdjusted hazard ratioAdverse CV eventsAtherosclerotic cardiovascular diseaseCox regression modelStandard of careEvent rate ratioCV deathCV eventsEmpagliflozin groupPlacebo patientsRecurrent hospitalisationsCV diseasePlacebo groupFirst eventHazard ratio248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial
INZUCCHI S, ZINMAN B, GEORGE J, MATTHEUS M, EYNATTEN M, WANNER C, HAUSKE S. 248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial. Diabetes 2019, 68 DOI: 10.2337/db19-248-or.Peer-Reviewed Original ResearchNon-proteinuric chronic kidney diseaseEffect of empagliflozinChronic kidney diseaseCardiorenal outcomesBoehringer Ingelheim PharmaceuticalsEMPA-REGCV deathKidney diseaseJanssen PharmaceuticalsEli LillyAdverse cardiorenal outcomesComposite kidney outcomeLower proteinuria levelsPrior CV diseaseSubgroup of patientsStrong risk predictorType 2 diabetesAdvisory PanelCKD populationKidney outcomesOvert albuminuriaOvert proteinuriaCause mortalityCV diseaseLower eGFR
2018
124 Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial
Verma S, Mazer C, Fitchett D, Inzucchi S, George J, Pfarr E, Woerle H, Zinman B. 124 Empagliflozin Reduces Mortality and Hospitalization for Heart Failure in Patients with Type 2 Diabetes and Peripheral Artery Disease: A Sub-Analysis of the EMPA-REG OUTCOME Trial. Canadian Journal Of Diabetes 2018, 42: s43. DOI: 10.1016/j.jcjd.2018.08.129.Peer-Reviewed Original ResearchRelationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort
RASOULI N, COHEN R, DEFRONZO R, INZUCCHI S, ISMAIL-BEIGI F, KAHN S, UTZSCHNEIDER K, LACHIN J, YOUNES N. Relationship between Baseline Phenotype and Measures of Insulin Sensitivity and Beta-Cell Responses in the GRADE Cohort. Diabetes 2018, 67 DOI: 10.2337/db18-1822-p.Peer-Reviewed Original ResearchC-peptide responseBaseline phenotypic characteristicsDisposition indexInsulin sensitivityBoehringer Ingelheim PharmaceuticalsΒ-cell functionT2D durationJanssen PharmaceuticalsBristol-Myers Squibb CompanyNational Diabetes Education ProgramBoehringer Ingelheim GmbHBeta-cell responseType 2 diabetesΒ-cell responseDiabetes education programΒ-cell dysfunctionWaist circumferenceBlood InstituteKidney diseaseNational HeartAbbVie Inc.Grade cohortsCelgene CorporationDisease controlBaseline phenotype
2016
How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies
Inzucchi S, Matthews D. How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies. 2016, 471-492. DOI: 10.1002/9781118924853.ch33.Peer-Reviewed Original ResearchType 2 diabetesMultiple pathophysiological defectsGlucose-lowering agentsSide effect profileAmerican Diabetes AssociationRecent position statementStudy of DiabetesMechanism of actionComplementary regimensManagement of peopleDiabetes AssociationCombination therapyPathophysiological defectsAntihyperglycemic agentsDrug therapyClinical practiceType 2Clinical useEuropean AssociationDiabetesIndividual riskPosition statementTherapyAssociationRegimensEFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK
Fitchett D, Inzucchi S, Lachin J, Wanner C, Mattheus M, Johansen O, Woerle H, Broedl U, Zinman B. EFFECT OF EMPAGLIFLOZIN ON MORTALITY AND CAUSES OF DEATH IN PATIENTS WITH TYPE 2 DIABETES AT HIGH CARDIOVASCULAR RISK. Canadian Journal Of Cardiology 2016, 32: s122-s123. DOI: 10.1016/j.cjca.2016.07.182.Peer-Reviewed Original ResearchLBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE
Lee D, Monteiro P, Clark D, Hantel S, Woerle H, Inzucchi S, Fitchett D. LBPS 02-52 EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE. Journal Of Hypertension 2016, 34: e520. DOI: 10.1097/01.hjh.0000501423.64635.bd.Peer-Reviewed Original ResearchHeart failure hospitalizationHigh cardiovascular riskCardiovascular deathFailure hospitalizationHeart failureStandard of careType 2 diabetesEmpagliflozin groupCardiovascular riskMajor adverse cardiovascular eventsEMPA-REG OUTCOME trialEMPA-REG OUTCOMEAdverse cardiovascular eventsEffect of empagliflozinHeart failure outcomesMedian observation timeRisk of hospitalizationCardiovascular eventsPlacebo groupAdverse eventsEffect of ageOutcome trialsSafety profileMean ageBaseline age
2011
SCREENING ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES FOR SILENT MYOCARDIAL ISCHEMIA: IMPORTANT GENDER DIFFERENCES FROM THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS (DIAD) STUDY
Tandon S, Bansal S, Inzucchi S, Staib L, Davey J, Chyun D, Young L, Wackers F. SCREENING ASYMPTOMATIC PATIENTS WITH TYPE 2 DIABETES FOR SILENT MYOCARDIAL ISCHEMIA: IMPORTANT GENDER DIFFERENCES FROM THE DETECTION OF ISCHEMIA IN ASYMPTOMATIC DIABETICS (DIAD) STUDY. Journal Of The American College Of Cardiology 2011, 57: e745. DOI: 10.1016/s0735-1097(11)60745-6.Peer-Reviewed Original Research